---
title: "Malaria and Leishmaniasis"
title-slide-attributes:
  data-background-image: /images_malaria/mosquito.png
format:
  revealjs:
    theme: [default, custom2.scss]
    touch: true
    controls: true
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: true
    incremental: true
    chalkboard: true
bibliography: Malaria.bib
csl: diagnostic-microbiology-and-infectious-disease.csl
---

## Parasitic Diseases: Malaria and Leishmaniasis {background-image="/images_malaria/mosquito.png" background-opacity="0.5"}

<br>

<br>

Russell Lewis <br> Associate Professor, Infectious Diseases <br> Department of Molecular Medicine <br> <br>MEP 2491 Infectious Diseases <br> 2 May 2023 <br> <br> ![](800-unipd.svg){fig-align="left" width="300"}

## Objectives

## Protozoa "first animals"

+-----------------+-----------------------------+-------------------------------------------------------+
| Means of spread | Habitat                     | Intracellular                                         |
|                 |                             |                                                       |
|                 | Extracellular               |                                                       |
+=================+=============================+=======================================================+
| Insect-borne\*  | African trypanosome (blood) | *Plasmodium* (liver, red blood cells)                 |
|                 |                             |                                                       |
|                 |                             | *Leishmania* (macrophage)                             |
|                 |                             |                                                       |
|                 |                             | South-America trypanosome (macrophage, muscle, nerve) |
+-----------------+-----------------------------+-------------------------------------------------------+
| Water-born      | Amoeba (gut)                | Toxoplasma (macrophage)                               |
|                 |                             |                                                       |
|                 | *Giardia* (gut)             |                                                       |
|                 |                             |                                                       |
|                 | *Cryptosporidium* (gut)     |                                                       |
|                 |                             |                                                       |
|                 | *Isospora* (gut)            |                                                       |
|                 |                             |                                                       |
|                 | *Trichomonas* (urogenital)  |                                                       |
+-----------------+-----------------------------+-------------------------------------------------------+

::: aside
\*The protozoa carried by inset vectors are mainly confined to tropics by the distribution of of the vectors
:::

## World Malaria Day

![](images_malaria/whomalaria.png)

<br>

## The pathogen

<br>

![](images_malaria/Plasmodium.png){fig-align="center" width="600"}

## The vector

<br>

![Malaria is transmitted by the bite of *Plasmodium*-infected female mosquitoes of the *Anophelus* genus](images_malaria/mosquito2.png){fig-align="center" width="600"}

## Malaria endemic regions

<br>

![](images_malaria/map.png){fig-align="center" width="800"}

::: aside
[@phillips2017a]
:::

## The impact of malaria on humans is <br> is staggering {.smaller}

<br>

-   Kills roughly 2000 people per day, most of whom are children in Africa

-   The strongest documented force for evolutionary selection in the recent history of the human genome

    -   Malaria is the evolutionary driving force behind the most common Mendelian diseases of humankind: sickle-cell disease, thalassemia, glucose-6-phosphatase deficiency, and other erythrocyte defects

-   Malaria was once prevalent throughout much of the inhabited world, but has been eliminated from the USA and Canada, Europe, and Russia (chloroquine-based treatment, large-scale insecticide using DDT)

    -   Malaria prevalence resurged in tropical countries from the 1970s to the 1990s because of a combination of relaxation of control efforts, increasing antimalarial drug resistance, and insecticide resistance in the mosquito vectors
    -   More selective vector control approaches (insecticide bed nets, indoor residual spraying) have led to a reduction in some areas of the world in the last 20 years

-   Growing resistance to insecticides in mosquitoes (*Anopheles gambiae)*

    -   Of the 78 countries that monitor insecticide resistance, 60 have reported resistance
    -   Increasing resistance to first-line XXXXX

::: aside
[@kwiatkowski2005a; @phillips2017a]
:::

## Trends in Malaria death rates in 2021

```{=html}
<iframe src="https://ourworldindata.org/grapher/malaria-death-rates-by-age" loading="lazy" style="width: 100%; height: 600px; border: 0px none;"></iframe>
```
<div>

Source: Our World in Data

</div>

## Malaria deaths by age

```{=html}
<iframe src="https://ourworldindata.org/grapher/malaria-deaths-by-age" loading="lazy" style="width: 100%; height: 600px; border: 0px none;"></iframe>
```
<div>

Source: Our World in Data

</div>

## Share of children with fever receiving appropriate anti-malarial drug

```{=html}
<iframe src="https://ourworldindata.org/grapher/share-of-children-with-a-fever-receiving-antimalarial-drugs?time=2018" loading="lazy" style="width: 100%; height: 600px; border: 0px none;"></iframe>
```
<div>

Source: Our World in Data

</div>

## Pathogenesis {background-image="/images_malaria/mosquito2.png" background-opacity="0.5"}

## Plasmodium spp. life cycle

![](images_malaria/lifecycle.png){fig-align="center" width="800"}

::: aside
[@phillips2017]
:::

## Clinical presentation

<br>

-   First symptoms are typically experienced 2-4 weeks after mosquito bite
-   Asexual replication in RBCs results in subsequent waves of merozoite invasion (increased parasite density) and paroxysms of chills, fevers and sweats and other manifestations of disease with merozoite release
-   Cycle repeats every:
    -   24 hours *Plasmodium knowlesi*
    -   48 hours *Plasmodium falciparam, Plasmodium vivax, Plasmodium ovale*
    -   72 hours *Plasmodium malaria*
-   Some *P. vivax* and *P. ovale* can postpone development in liver as latent forms called hypnozoites (not eradicated by standard therapy e.g., chloroquine) directed against blood stages.
-   Hyponozoite development can resume months to years later leading to relapse
    -   Relapse can be prevented with primaquine, but only moderately effective

## Five species of *Plasmodium* infection in humans

<br>

+-------------------+-------------+-----------------------------+------------------------------------------------------------------------------------------------+
| *Plasmodium spp*. | Liver stage | Blood cycle and fever peaks | Disease features                                                                               |
+===================+=============+=============================+================================================================================================+
| *P. falciprium*   | 6-14 days   | 48h (tertian)               | Major complications, fatal without treatment                                                   |
+-------------------+-------------+-----------------------------+------------------------------------------------------------------------------------------------+
| *P. vivax*        | 12-17 days  | 48h (tertian)               | Seldom fatal, but can better survive unfavourable temperatures and remain dormant in the liver |
+-------------------+-------------+-----------------------------+------------------------------------------------------------------------------------------------+
| *P. malariae*     | 13-40 days  | 72h (quartan)               | Nephrotic syndrome                                                                             |
+-------------------+-------------+-----------------------------+------------------------------------------------------------------------------------------------+
| *P. ovale*        | 9-18 days   | 48h (tertian)               |                                                                                                |
+-------------------+-------------+-----------------------------+------------------------------------------------------------------------------------------------+
| *P. knowlowsi*    | 9-12 days   | 24h (quotidian)             | Southeast Asia, monkey                                                                         |
+-------------------+-------------+-----------------------------+------------------------------------------------------------------------------------------------+
|                   |             |                             |                                                                                                |
+-------------------+-------------+-----------------------------+------------------------------------------------------------------------------------------------+

## *Plasmodium* infection humans

<br>

::: nonincremental
-   ***Plasmodium falciparum*** **(malignant tertain)**

    -   Most deadly (1 million deaths per year- anaemia and cerebral malaria)

    -   *Sequestration*- parasitized RBCs: glomerulonephritis, hypoglycaemia, pulmonary edema

    -   Almost all deaths are caused by this species

![](images_malaria/patho1.jpeg){width="600"}
:::

## Malaria- acquired immunity

<br>

-   Not sterilizing, instead "disease-controlling immunity" despite presence of parasites in bloodstream

-   Immunity increases with age, cumulative episodes and time living in endemic area

    -   Short-lived without continued exposure to different *P. falciparum* variants

    -   Antigen switching results in new waves of parasitemia, escape from antibody responses

    -   Disease controlling immunity (premunition) after repeated infection episodes associated with development of antibody repertoire that recognizes the full spectrum PfEMP-1 variant antigens

    -   Antibodies play a role in antibody-dependent cellular cytotoxicity, opsonization for uptake, destruction by splenic macrophages, interference with PfEMP-1 mediated cytoadhearance interactions

        ![](images_malaria/recurrent.jpeg){width="400"}

## Underlying conditions associated with severe malaria

-   Splenectomy - high parasite loads

    -   Splenomegaly common in malaria (removal of infected erythrocytes) but contributes to anaemia associated with disease

-   Pregnancy

## References

<br>
